title: [Calcium antagonists: current and future applications based on new evidence. The mechanisms on lowering serum uric acid level by calcium channel blockers].
abstract: In hypertensive subjects, their serum uric acid levels tend to be higher because of decreasing urinary secretion or overproduction of uric acid. Among calcium channel blockers (CCBs) , long acting nifedipine and cilnidipine reveal serum uric acid lowering action. They decrease the production of uric acid precursor in skeletal muscles under anaerobic condition induced by hypertension or insulin resistance. Hyperuricemia is considered to be a risk factor of not only gout but also renal and cardiovascular diseases, thus, it is important to use CCBs without adverse effect on uric acid metabolisms.
authors.affiliation: Division of Molecular Medicine and Therapeutics, Department of Multidisciplinary Internal Medicine, Tottori University Faculty of Medicine, Japan.
authors.forename: Einosuke
authors.initials: E
authors.lastname: Mizuta
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Hamada
authors.forename: Osamu
authors.initials: O
authors.lastname: Igawa
authors.forename: Chiaki
authors.initials: C
authors.lastname: Shigemasa
authors.forename: Ichiro
authors.initials: I
authors.lastname: Hisatome
mesh_terms: D000693:Anaerobiosis; D002121:Calcium Channel Blockers / Q000494:pharmacology* / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology; D003864:Depression, Chemical; D006073:Gout / Q000209:etiology; D006801:Humans; D006973:Hypertension / Q000150:complications; D033461:Hyperuricemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D019271:Hypoxanthine; D007674:Kidney Diseases / Q000209:etiology; D018482:Muscle, Skeletal / Q000378:metabolism; D012307:Risk Factors; D014527:Uric Acid / Q000097:blood*
chemical_list: D002121:Calcium Channel Blockers; D014527:Uric Acid; D019271:Hypoxanthine